Shandong Xinhua Pharma
Shandong Xinhua Pharmaceutical Company Limited, commonly referred to as Xinhua Pharma, is a prominent player in the pharmaceutical industry, headquartered in Shandong, China. Established in 1996, the company has made significant strides in the development and production of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms.
With a strong focus on research and development, Xinhua Pharma has carved out a niche in the production of high-quality generic medications and innovative therapies. The company is recognised for its commitment to quality and compliance with international standards, which has bolstered its market position both domestically and globally. Notable achievements include various certifications and partnerships that enhance its reputation as a reliable supplier in the pharmaceutical sector.
-5 vs industry average
Shandong Xinhua Pharma’s score of 33 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Shandong Xinhua Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Shandong Xinhua Pharma's reported carbon emissions
In 2025, Shandong Xinhua Pharmaceutical Co., Ltd reported total carbon emissions of approximately 909.6 million kg CO2e. This figure includes Scope 1 emissions of about 325,250 kg CO2e, Scope 2 emissions of approximately 282.1 million kg CO2e, and Scope 3 emissions of around 627.2 million kg CO2e. The company has committed to near-term climate targets, although specific reduction targets have not been detailed. As of December 2025, Shandong Xinhua Pharma is classified as "Committed" to near-term targets under the Science Based Targets initiative (SBTi). Over the previous years, emissions have shown fluctuations, with 2024 emissions recorded at approximately 307.6 million kg CO2e (Scope 1: about 22.1 million kg CO2e, Scope 2: approximately 285.6 million kg CO2e) and 2023 emissions at around 260.6 million kg CO2e (Scope 1: about 18.9 million kg CO2e, Scope 2: approximately 241.7 million kg CO2e). Shandong Xinhua Pharma's emissions data is not cascaded from any parent company, indicating that the reported figures are independently sourced. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector in China, reflecting its commitment to addressing climate change through potential future initiatives.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Shandong Xinhua Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Shandong Xinhua Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative

Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsFrequently asked questions
Common questions about Shandong Xinhua Pharma’s sustainability data and climate commitments
Data year: 2025
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project